pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·May 13·1 min read
save

FDA Commissioner Marty Makary resigns, Kyle Diamantas named acting commissioner

May 13, 2026·read at STAT ↗RegulatoryNeutral

The U.S. Food and Drug Administration announced that Commissioner Marty Makary will step down from his position. The agency said that Kyle Diamantas, who currently oversees food regulation, will serve as the acting commissioner while a permanent replacement is identified.

According to internal sources, a faction within the Department of Health and Human Services had been dissatisfied with Makary's leadership and had explored options to remove him for several months. The resignation appears to be the result of that internal pressure.

The leadership change comes as the FDA continues to manage a range of ongoing initiatives, including drug approvals and safety oversight, and may influence the agency's strategic direction in the coming months.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Pharmalittle: We’re reading about FDA’s Makary resigning, a Lilly weight loss drug trial, and more”

read at STAT ↗
692 words · retrieved May 13
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
LILLY6NOVO2BRISTOLELI LILLY CONovo Nordisk Inc
drugs
FOUNDAYO4MOUNJARO4Ozempic4Wegovy4ZEPBOUND4orforglipron calcium4tirzepatide4Wegovy Pill3ObesityRybelsussemaglutide
topics
Obesity4Duchenne Muscular DystrophyGLP-1 receptorGene Therapy (AAV)Small Molecule

related stories

  • Jun 3STAT+: Pharmalittle: We’re reading about GLP-1 drugs and knees, FDA cell and gene therapy guidance, and moreSTAT
  • Sep 30Lilly builds commercial case for GLP-1 products over Novo with indirect analysesBioSpace
  • Sep 21Novo’s plan to hit $23B in revenue by 2035 leaves investors wantingBioSpace
  • Aug 27Myriad catalysts on deck for obesity’s brightest stars as market continues to accelerateBioSpace
  • Aug 19Novo takes first round of oral obesity duel. Can it stay ahead of Lilly?BioSpace